DANBURY, CT — A Danbury-based pharmaceutical company has reported positive results from an early-stage clinical trial of an experimental treatment for a serious lung disease.
MannKind Corporation announced July 29 that its Phase 1b INFLO-1 trial evaluating inhaled nintedanib dry powder in patients with idiopathic pulmonary fibrosis met its primary objective. The company reported that the treatment was generally safe and well tolerated.
Idiopathic pulmonary fibrosis, or IPF, is a chronic disease that causes scarring in the lungs and makes breathing increasingly difficult.
The results represent an early step in the drug's development. The treatment remains investigational, and the trial's findings do not establish that it is effective at treating the disease.
Danbury Mayor Roberto Alves highlighted the results in a city announcement, pointing to MannKind's research and manufacturing operations in the city.
"There is something incredibly special about knowing that medicines with the potential to change lives are being researched, developed and manufactured right here in Danbury," Alves said.
The mayor also described MannKind as a longtime community partner that provides local jobs and develops treatments for patients beyond Danbury.
MannKind's work spans several therapeutic areas, including diabetes, cardiometabolic disease and serious lung conditions. Its research includes inhaled therapies developed using the company's proprietary Technosphere technology.
City officials said they plan to continue working with MannKind as the company explores opportunities for growth in Danbury.
Sign up for free local newsletters and alerts for the
Danbury Patch
Patch.com is the nationwide leader in hyperlocal news.
Visit Patch.com to find your town today.